Evidence map›Paper›PMID 28078014›Full record

ArticleAmerican journal of translational research2016

MiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppressing TGIF2.

Songyan Wu, Xiangfeng He, Miao Li, Fangfang Shi, Di Wu, Meng Pan, Mei Guo, Rong Zhang, Shouhua Luo, Ning Gu and 1 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Nanotherapeutics for multiple myeloma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2018
    Review
  15. Article
  16. Article
  17. OncoTargets and therapy · 2018
    Article
  18. Identification of serum miR-34a as a potential biomarker in acute myeloid leukemia.Cancer biomarkers : section A of Disease markers · 2018
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Songyan WuDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast UniversityNanjing 210009, China; Changzhou Blood CenterChangzhou 213004, China.
Xiangfeng HeDepartment of Medical Oncology, Affiliated Tumor Hospital of Nantong University Nantong 226361, China.
Miao LiDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University Nanjing 210009, China.
Fangfang ShiDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University Nanjing 210009, China.
Di WuDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University Nanjing 210009, China.
Meng PanDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University Nanjing 210009, China.
Mei GuoDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University Nanjing 210009, China.
Rong ZhangDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University Nanjing 210009, China.
Shouhua LuoSchool of Biological Science & Medical Engineering, Southeast University Nanjing 210096, China.
Ning GuSchool of Biological Science & Medical Engineering, Southeast University Nanjing 210096, China.
Jun DouDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University Nanjing 210009, China.
Southeast University · CNNantong Tumor Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematological malignancy originated from B-cell line, multiple myeloma (MM), is a kind of plasma cells in bone marrow hyperplasia and cause of osteoclast-mediated skeletal destruction disease. MiR-34a plays an important epigenetic regulating role in malignant tumors and presents a therapeutic potential. In this study, we investigated the effects of overexpression of miR-34a in MM cancer stem cells (CSCs) on tumor growth and bone lesions. Here we showed that miR-34a overexpression inhibited cell proliferation, colony formation, and increased CSC apoptosis

Indexed as

cancer stem cellsmiR-34aMultiple myelomatransforming growth interaction factor 2

Identifiers

PMID28078014
PMCPMC5209494
OpenAlexW2972714976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.